Skip to content

Ophthalmic Compatibility During Seven Days of Continuous Wear of Silicone Hydrogel Lenses

Ophthalmic Compatibility During Seven Days of Continuous Wear of Silicone Hydrogel Lenses (P/318/08/C)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00934102
Acronym
QUINCE
Enrollment
57
Registered
2009-07-08
Start date
2009-08-31
Completion date
2009-09-30
Last updated
2012-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Brief summary

The purpose of this study is to assess the ophthalmic compatibility of three different silicone hydrogel lenses worn on an overnight basis for six nights.

Interventions

Investigational, silicone hydrogel, spherical soft contact lens

Commercially marketed, silicone hydrogel, spherical soft contact lens

DEVICEGalyfilcon A contact lens

Commercially marketed, silicone hydrogel, spherical soft contact lens

Sponsors

University of Waterloo
CollaboratorOTHER
CIBA VISION
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
17 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Is at least 17 years of age and has full legal capacity to volunteer * Is correctable to a visual acuity of 20/30 or better (in each eye) with their habitual vision correction * Has had an ocular examination in the last two years * Is a current soft (hydrogel or silicone hydrogel) contact lens wearer * Has clear corneas and no active ocular disease * Can be successfully fit with the lenses to be used in the study * Other protocol-defined inclusion/

Exclusion criteria

may apply

Design outcomes

Primary

MeasureTime frameDescription
Front Surface Lens DepositsPeriod 2, Day 6Protein and lipid deposits on the contact lens surface as assessed by the investigator using a biomicroscope, which magnifies the appearance of the contact lens on the wearer's eye. Deposits were graded on a scale of 0 to 4 with 0 being none and 4 being severe.

Countries

Canada

Participant flow

Pre-assignment details

Of the 57 subjects screened for the study, 11 did not start Period 1 due to personal reasons (7) and non-suitability (4). Period 1 established Day One measurements in order to monitor changes during Period 2.

Participants by arm

ArmCount
Overall
This reporting group includes all subjects who were screened for the study, whether or not they subsequently were dispensed.
57
Total57

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Period 1, One Night of WearPersonal Reasons100

Baseline characteristics

CharacteristicOverall
Age Continuous23.23 years
STANDARD_DEVIATION 4.04
Sex: Female, Male
Female
45 Participants
Sex: Female, Male
Male
12 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —
other
Total, other adverse events
0 / 300 / 300 / 30
serious
Total, serious adverse events
0 / 300 / 300 / 30

Outcome results

Primary

Front Surface Lens Deposits

Protein and lipid deposits on the contact lens surface as assessed by the investigator using a biomicroscope, which magnifies the appearance of the contact lens on the wearer's eye. Deposits were graded on a scale of 0 to 4 with 0 being none and 4 being severe.

Time frame: Period 2, Day 6

Population: Per Protocol. Only the data from participants who completed all study visits were analyzed.

ArmMeasureValue (MEAN)Dispersion
Lotrafilcon AFront Surface Lens Deposits0.68 Units on a ScaleStandard Deviation 0.35
Narafilcon AFront Surface Lens Deposits0.78 Units on a ScaleStandard Deviation 0.67
Galyfilcon AFront Surface Lens Deposits0.77 Units on a ScaleStandard Deviation 0.61

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026